GlassScriptPhysician profile
Emily V Murtha
NPI 1770637001
$4,307.40
in general payments reported to CMS, 2019-2025
25 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $636 · 2022: $1,201 · 2023: $981 · 2024: $816 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,471.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $725.45 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $476.36 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $400.75 | 2021-2025 | Dificid, Zerbaxa, Recarbrio |
| Viiv Healthcare Company | $300.94 | 2022-2025 | Dovato, Rukobia, Apretude |
| Melinta Therapeutics, LLC | $272.67 | 2021-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Paratek Pharmaceuticals, INC. | $251.67 | 2021-2023 | Nuzyra |
| Amgen INC. | $226.53 | 2021-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $218.51 | 2022-2025 | Arexvy, Shingrix |
| Pfizer INC. | $214.87 | 2023-2025 | |
| Lilly USA, LLC | $179.92 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Biotech, INC. | $175.31 | 2021-2023 | Symtuza |
| Shionogi INC | $147.83 | 2022-2024 | Fetroja |
| Abbott Laboratories | $132.48 | 2022-2025 | Freestyle Libre 3 |
| Cumberland Pharmaceuticals, INC. | $113.05 | 2021-2023 | Vibativ |
| Theratechnologies INC. | $97.76 | 2021-2023 | Trogarzo, Egrifta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $95.06 | 2024-2025 | Cresemba, Veozah |
| Astrazeneca Pharmaceuticals LP | $85.37 | 2022-2025 | Airsupra, Breztri |
| Gilead Sciences, INC. | $59.70 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.01 | 2021 | |
| Dynavax Technologies Corporation | $23.80 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.22 | 2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $18.55 | 2021 | |
| Seqirus USA INC | $17.27 | 2022 | |
| Intra-Sana Laboratories | $17.17 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Boston Scientific Corporation | $13.15 | 2024 | Orcapod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Murtha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.